Living autologous heart valves for minimally invasive implantable procedures. Large scale integrating project.
Approximately 1% of all new-borns suffer from congenital heart defects which cannot be treated efficiently due to the lack of growth of the clinically available "artificial" replacement materials, such as heart valve prostheses. Existing artificial heart valves have significant limitations including limited durability and/or the need for lifelong medication. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. Each of these operations can be potentially life threatening.
The five-year initiative LifeValve aims at developing a tissue engineered living heart valve which can be implanted by minimally invasive catheter technology. The valve is expected to grow in accordance with the growth of children, thereby minimise the need for future surgical intervention. In six scientific work packages under the umbrella of a work package devoted to the management, LifeValve combines two recent novel life science technologies – tissue engineering and minimally invasive implantation technology for the benefit of children with congenital heart disease. The technological objectives of this translational approach comprise (a) the development of intelligent biomaterial and stent system, (b) the in vitro creation of a living valve with the capacity of growth by tissue engineering methods and (c) a minimally invasive implantation technology (non-surgical procedure) of the LifeValve.
Researchers of the Medical University
he Medical University of Vienna is project partner under the leadership of Assoc. Prof. Mariann Gyöngyösi / Department of Medicine II.
Project coordinator: Prof. Dr. Dr. Simon P. Hoerstrup, Regenerative Medicine Program, University and UniversityHospital Zurich, Switzerland
Project partners: 8
|Topic||FP7-HEALTH-2009-single stage: Living autologous heart valves for minimally invasive implantable procedures. Large scale integrating project|
|Project duration||11/2009 – 10/2014|
|Funding volume, total||€ 9.8 Mio|
|Funding volume, Medical University of Vienna||€ 215 480|